Stutzman D, Dopheide J
Many participants report reduced snoring, better sleep quality, and improved daytime alertness within the first few months of treatment
No, dsip nasal spray is sold for laboratory research use only and is not for human or veterinary consumption
For instance, many of our first-line oral treatments for type 2 DM (except for metformin) are associated with weight gain.9 With time, control of glycemia becomes more and more ineffective, at which point therapy is intensified with insulin, further exacerbating the weight gain.10 Therefore, it seems counterintuitive to treat a disease for which obesity is one of the main risk factors with medications that promote weight gain
Apply a thin layer to the injection site after initial pressure application
In one Phase 2 trial, the drug, called elecoglipron, led patients with obesity to lose 11.2% of their weight after 36 weeks